Novel therapies, including enzastaurin, in the treatment of ovarian cancer

By Vergote Ignace  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 5, 2014-05 ,pp. : 579-598

Informa Healthcare

Access to resources Recommend Favorite

Enzastaurin 525 mg/day is the recommended dosage for patients with cancer, and it is well tolerated at dosages of up to 700 mg/day

By  

Inpharma, Vol. 1, Iss. 1554, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies

By Ysebaert Loic   Morschhauser Franck  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 8, 2011-08 ,pp. : 1167-1174

Informa Healthcare

Access to resources Recommend Favorite

Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma

By Civallero Monica   Cosenza Maria   Bari Alessia   Sacchi Stefano  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 8, 2011-08 ,pp. : 1029-1031

Informa Healthcare

Access to resources Recommend Favorite

Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 12-28

Bentham Science Publishers

Access to resources Recommend Favorite